Kristina Penniston, commented that these patients could potentially serve as a control group when analyzing how obesity affects stone risk
Both studies included several dose groups to examine dose-response patterns, a common feature of Phase 2 research.[1][2] Lillys 2026 materials describe Phase 3 programs involving adults with obesity or overweight and related comorbidities, as well as separate cohorts of adults with type 2 diabetes.[4][5] These populations remain clinical research groups rather than approved treatment indications
It may be genuinely synergistic
Potential Benefits for Lifters and Athletes For those who train, allulose might offer glycogen-sparing effects , helping preserve energy stores during workouts
Zangabad PS, Vasani RB, Tong Z, Anderson D, Rudd D, Hick CA, et al
The other important aim of modern anti-diabetic therapy is to reduce mortality risk and long-term complications of T2DM, such as cardiovascular, renal and neurological damage